New data using Antaros full liver analysis presented at EASD in Berlin

There was a great interest at the annual European Association for the Study of Diabetes (EASD) 2018 in Berlin for the results generated by Antaros Medical. The two studies were done in collaboration with AstraZeneca and MedImmune, respectively.

Precision is key when choosing methods for decision making in drug development to ensure accurate understanding of efficacy. Metabolic dysfunction-associated steatotic liver disease (MASLD; previously called non-alcoholic fatty liver disease or NAFLD) and metabolic dysfunction-associated steatohepatitis (MASH; previously called non-alcoholic steatohepatitis or NASH) studies using MRI-PDFF covers the entire liver in a single breath-hold and enables quantification of changes in total liver fat.

Figure 1. Lars Johansson, CSO, at EASD 2018

Lars Johansson, CSO, Antaros Medical comments: “The Antaros methodology measures both the liver volume and liver fat from the entire liver. This is of importance to improve the accuracy of liver fat measurements and allows for further understanding of drug specific mode of action.”

Figure 2. PDFF and Liver Volume

Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes

ePoster # 647

Authors: Lars Johansson, Paul Hockings, Eva K Johnsson, Jill Maaske, Ricardo Garcia-Sanchez, John P Wilding

MEDI0382, a glucagon-like peptide 1/glucagon receptor dual agonist, significantly reduces hepatic fat content in subjects with type 2 diabetes

Abstract # 727

Authors: Philip Ambery, Lan-Feng Tsai, Darren Robertson, Boaz Hirshberg, Paul Hockings, Lars Johansson Meena Jain.